Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated
